GC
ITCI

Guggenheim Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Guggenheim Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,241
Closed -$2.8M – 1700
2025
Q1 		$2.8M Sell
21,241
-8,878
-29% -$1.11M 0.03% 551
2024
Q4 		$2.52M Sell
30,119
-7,133
-19% -$586K 0.02% 577
2024
Q3 		$2.73M Sell
37,252
-1,017
-3% -$76.4K 0.02% 720
2024
Q2 		$2.62M Sell
38,269
-2,785
-7% -$193K 0.02% 726
2024
Q1 		$2.84M Buy
41,054
+1,245
+3% +$85.6K 0.02% 761
2023
Q4 		$2.85M Buy
39,809
+22,356
+128% +$1.29M 0.02% 717
2023
Q3 		$909K Buy
17,453
+304
+2% +$17.7K 0.01% 1146
2023
Q2 		$1.09M Sell
17,149
-1,453
-8% -$90.5K 0.01% 1129
2023
Q1 		$1.01M Buy
18,602
+6,957
+60% +$336K 0.01% 1182
2022
Q4 		$616K Buy
11,645
+2,288
+24% +$115K 0.01% 1396
2022
Q3 		$435K Buy
9,357
+638
+7% +$33.3K ﹤0.01% 1534
2022
Q2 		$498K Sell
8,719
-664
-7% -$37.6K ﹤0.01% 1583
2022
Q1 		$574K Buy
9,383
+1,692
+22% +$87.9K ﹤0.01% 1635
2021
Q4 		$402K Buy
+7,691
New +$323K ﹤0.01% 1773
2015
Q4 		– Sell
-23,014
Closed -$922K – 3094
2015
Q3 		$922K Buy
+23,014
New +$751K ﹤0.01% 2141

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Guggenheim Capital's ITCI Position: Q2 2025 in Review

Guggenheim Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 21,241 shares — an estimated $2.8M sold.

Guggenheim Capital first reported a position in ITCI in Q3 2015 and held it in 15 quarters. The position peaked at $2.85M in Q4 2023. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Guggenheim Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Guggenheim Capital sold 21,241 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.8M.
  • Guggenheim Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 15 quarters.
  • Guggenheim Capital's Intra-Cellular Therapies Inc. position peaked at $2.85M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Guggenheim Capital's 13F filing for Q2 2025, filed 13 Aug 2025.